Company intelligence / Profile preview

IpiNovyx Bio

New York City, New York, USAipinovyx.com ↗

Ownership: Private
Development stage: Other

Overview

IpiNovyx Bio is advancing a proprietary platform of highly selective, reversible immunoproteasome inhibitors with promising preclinical efficacy and safety profiles. The company is preparing to submit its first IND application and enter clinical trials targeting autoimmune and inflammatory diseases. Their compounds are designed to modulate immune responses without killing immune cells, potentially offering a safer alternative to current immunosuppressive therapies.

Therapeutic areas: ImmunologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Weill Cornell MedicineHospital for Special Surgery Research InstituteTri-Institutional Therapeutics Discovery InstituteEli LillyViva BioInnovator/Viva BiotechOpaleye ManagementAlexandria Venture Investments

Beyond the preview

Go deeper on IpiNovyx Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IpiNovyx Bio.

Explore the full profile